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Platinum/taxane combinations are widely used in patients with carcinoma of unknown primary (CUP), yielding response rates of 30%
and median overall survival of 9–11 months in selected patients. Yet these combinations have not been subject to a randomised trial
to overcome selection bias, a major problem in CUP. We randomised 92 patients to either paclitaxel/carboplatin (arm A) or the
non-platinum non-taxane regimen gemcitabine/vinorelbine (arm B). The primary endpoint was rate of practicability as defined:
application of X2 cycles of therapy (1) with a maximal delay of 1 week (2) and survival of X8 months (3). Practicability was shown in
52.4% (95% CI 36–68%) in arm A and in 42.2% (95% CI 28–58%) in arm B, respectively. The median overall survival, 1-year survival
-rate and response rate of patients treated in arm A was 11.0 months, 38, and 23.8%, arm B 7.0 months, 29, and 20%. In conclusion,
the paclitaxel/carboplatin regimen showed clinically meaningful activity in this randomised trial (Clinical trial registration number 219,
‘Deutsches KrebsStudienRegister’, German Cancer Society.)
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Despite improved diagnostic tools (e.g., imaging procedures and
histologic/molecular workup), carcinoma of unknown primary site
(CUP) remains a common clinical problem and represents 2–4%
of all malignancies (Levi et al, 2002; van de Wouw et al, 2002).
Histologically, adenocarcinoma (40–50%) and poorly differen-
tiated carcinoma including poorly differentiated adenocarcinoma
(30–40%) account for the vast majority of cases. In recent years
comparable clinical behaviour of both groups was demonstrated
and ‘treatable’ subsets were identified: resectable disease, squa-
mous or poorly differentiated carcinoma in upper cervical nodes,
women with axillary nodes (suggestive of occult breast cancer),
women with peritoneal carcinomatosis (suggestive of occult
ovarian cancer), young men with features of extragonadal germ
cell cancer (young age, poorly differentiated carcinoma, midline
presentation, multiple pulmonary nodules), neuroendocrine carci-
noma, and possibly colon-cancer-type carcinoma (Varadhachary
et al, 2008). Unfortunately, these subsets represent only 5–10% of
cases (Pavlidis and Fizazi, 2005). In the remaining patients
improved results with recent empiric therapies incorporating
new chemotherapeutic agents have replaced the former attitude of
widespread nihilism in the majority of oncologists.
Platinum/taxane combinations are widely used in patients with
CUP, yielding response rates of about 30% and a median survival
of 9–11 months in selected patients in large phase II studies
(Hainsworth et al, 1997; Greco et al, 2002). Gemcitabine has shown
efficacy in second-line treatment and has recently been incor-
porated in first-line regimen. Combined with cisplatin the
response rate was 55% with a median survival of 8 months (Culine
et al, 2003). The combination with carboplatin resulted in a 31%
response rate with equal survival (Pittman et al, 2006). Gemcita-
bine in combination with docetaxel yielded a response rate of 40%
with a median survival of 10 months (Pouessel et al, 2004).
Vinorelbine has proven efficacy in many malignancies, especially
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snon-small cell lung cancer (NSCLC) and breast cancer, with only
anecdotal experience in CUP syndrome.
To date only eight randomised trials have been published in
CUP syndrome, none of these addressing the efficacy of platinum/
taxane combinations (Fizazi and Schmoll, 2006). This study was
designed to investigate carboplatin/paclitaxel and the non-
platinum non-taxane regimen gemcitabine/vinorelbine in a pro-
spective randomised multicenter phase II trial.
PATIENTS AND METHODS
Patients with histologically/cytologically proven adeno- or un-
differentiated metastatic CUP site were eligible for participation in
this multicenter study. Complete history, physical examination,
chest X-ray, CT scan of chest and abdomen, upper intestinoscopy,
colonoscopy, mammography (in women), PSA, AFP, and hCG
(in men), and directed workup of symptomatic areas were
mandatory before inclusion. Patients with resectable disease,
men with features of the extragonadal germ cell cancer syndrome
(o50 years, lymph node involvement predominantly retroperito-
neal or mediastinal), and women with predominant axillary
lymph nodes and suspected breast cancer were excluded.
Further inclusion criteria were ECOG PS o3, adequate bone
marrow, renal and hepatic function (absolute neutrophil count
41000ml
 1 and thrombocytes X100000ml
 1, creatinine
p2 UNL, bilirubine p2 UNL, AST/ALT p5 UNL), no prior
chemotherapy, and the absence of brain metastasis or severe
comorbidity. Age had to be within 18–80 years. Pregnant women
were also excluded.
After written informed consent was obtained, patients were
randomised to either arm A, paclitaxel 175mgm
 2 day 1 (d1)
intravenously (3h) and carboplatin AUC¼5mgml
 1min
 1 d1 i.v.
(30min), or to arm B, gemcitabine 1gm
 2 d1þ8 i.v. (30min) and
vinorelbine 25mgm
 2 d1þ8 i.v. (rapid short infusion). Cycles in
both arms were repeated every 21 days. Response was assessed
according to the WHO criteria every three cycles and every 3
months after end of treatment for at least 8 months. Patients with
responsive or stable disease remained on therapy for a maximum
of six cycles. Treatment after the completion of the planned six
cycles of chemotherapy or after progression was at the discretion
of the treating physician.
All toxicities were graded according to the NCI common toxicity
criteria, version 3. Blood counts were checked weekly, clinical
chemistry every three weeks. Dose reduction or delay of therapy
was performed according to the following criteria: all patients
received full dose of therapy on day 22 with leukocytes 42500ml
 1
and thrombopenia grade p1. In case of leukopenia p2500ml
 1 or
thrombopenia grade X2 therapy was postponed for 1 week, in case
of grade X3 leuko- or thrombopenia at day 22, treatment was
reduced by 25% for all following cycles. For neurotoxicity CTC
grade 2 treatment was delayed until recovery or reduced by 25%
(at the discretion of the treating physician). In case of
neurotoxicity grade 3 and 4 or any other CTC grade 4 toxicity
(apart from alopecia and haematological toxicity) the patient was
removed from the study leaving further treatment at the discretion
of the treating physician.
The primary objective of the study was the composite endpoint
‘practicability’ of (1) treatment with at least two cycles of therapy
(2) with a maximal delay of 1 week and (3) survival of X8 months.
This endpoint combines clinically relevant criteria concerning
overall survival and the feasibility of the study therapy. It has been
developed by the German Cancer Research Center and been used
before in a randomised phase II trial (Manegold et al, 2005). It is in
accordance to the EORTC guidelines to evaluate the response to
treatment in solid tumours, which state that ‘measures of
antitumor activity, other than tumour shrinkage, may allow
investigation of cytostatic agents in phase II trials more appro-
priately’ (Therasse et al, 2000). The aim of the trial was to detect a
practicability rate of 430% for each arm, respectively. The
primary analyses were the two-sided 95% confidence intervals of
the practicability rate for each arm. In each arm, assuming a
practicability rate of 50%, 50 patients were to be evaluated to
detect a practicability rate of 430% with 90% power at the 5%
significance level. Secondary objectives were response rate, overall
survival, progression-free survival and quality of life (measured by
the EORTC QLQ C 30 questionnaire). Overall survival was
calculated from the day of randomisation. Progression-free
survival was measured from the day of randomisation until
tumour progression or death was documented. Survival curves
were constructed using the Kaplan–Meier method. Both arms were
analysed separately, no adjustment for multiplicity was performed.
Randomisation was accomplished using the permuted block
randomisation with a block size or balancing interval of six
patients. SAS, Version 9.1, was applied for all data analyses and the
random number generation.
The study was approved by the local ethical committees
and performed according to GCP standards. Source data verifi-
cation was performed at every site throughout the study.
The database was located at the KKS Mainz (Coordination
Center for Clinical Studies, University of Mainz, Germany)
which performed all descriptional and statistical analyses
independently from the investigators. The trial was approved
and registered by the German Cancer Society (Approval
‘Gutesiegel A’, clinical trial registration number 219, ‘Deutsches
KrebsStudienRegister’).
RESULTS
From September 2001 through June 2004, 92 patients were
randomised in 25 German centers, contributing 1–16 patients
each. Five patients had to be excluded from analyses due to major
protocol violations before start of treatment: identification of the
primary tumour (N¼2), major protocol violations (N¼3)
(Figure 1). Of the remaining 87 eligible patients all were evaluable
for the primary endpoint, 42 patients in arm A and 45 patients in
arm B.
Patient characteristics
Patient characteristics are given in Table 1. Both groups were well
balanced with respect to gender, age, tumour burden, manifesta-
tion above or below the diaphragm, and LDH elevation. However,
there was a slight tendency to a better ECOG performance score
and to more lymph node involvement in arm A and a slight
tendency to more liver involvement and pleural/peritoneal
effusions in arm B (without reaching statistical significance). In
the group of 16 patients with peritoneal involvement at presenta-
tion, 9 patients had X3 and 5 patients had 2 involved sites. Only
two patients had peritoneal involvement only (both female, arm B),
ovarian cancer was ruled out in both. Overall, both arms
represented a high-risk population of patients with CUP syndrome
with a large tumour burden and a high proportion of patients with
liver involvement.
Delivery of scheduled chemotherapy
The median number of cycles was 5.5 in arm A and 3 in arm B, the
mean number 4.3 and 3.6, respectively. In arm A 1–2 cycles were
delivered to 10 patients, 3–5 cycles to 11 patients, and all planned
6 cycles to 21 patients. In arm B, 15 patients received p2, 15
patients p5 and 15 patients all 6 cycles. Mean dose intensity was
X90% for each drug throughout the study.
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Major toxicities are listed in Table 2. As expected, haematological
toxicity was more common in arm B, whereas alopecia and
hypersensitivity reactions (leading to withdrawal from the study in
three patients) were more common in arm A. Febrile neutropenia
was rare in both arms with a very low proportion of grade 3–4
infections. Three patients died from treatment-related toxicity. In
arm B, one patient with extensive liver metastasis died of liver
failure 3 days after the first application of chemotherapy, a second
patient died of neutropenic sepsis 17 days after the first application
of chemotherapy. In arm A, one patient was found dead at home
10 days after application of the second cycle of therapy, tumour
progression combined with a major infection was the most
probable cause.
Efficacy
All patients were evaluable for the primary endpoint. The rate of
practicability (as defined above) was 52.4% (22out of 42) in arm A
and 42.2% (19 out of 45) in arm B, respectively (Table 3). Only in
arm A the 95% CI was above the threshold of 30%, so this arm has
proven to be practical as defined for the primary endpoint. Of 87,
79 patients were evaluable for response (38 out of 42 patients in
arm A, and 41 out of 45 patients in arm B; Figure 1). There were no
complete responders with either regimen. In the intention-to-treat
analysis the overall response rate was 23.8% in arm A and 20.0% in
arm B, respectively (Table 3).
The median progression-free survival was 6.1 (4.4–7.7) months
in arm A and 3.2 (2.2–4.8) months in arm B, the median overall
survival 11.0 (6.9–13.1) months and 7.0 (4.6–11.9) months for arm
A and B, respectively. One-year survival rates were 38 (23–52)%
and 29 (15–42)% for arms A and B (Figures 2 and 3). Data are
mature; median follow-up in arm A was 18.5 months with 7
patients remaining at risk, arm B 14.6 months and 6 patients,
respectively.
A Cox proportional hazard analysis failed to show a significant
influence of ECOG performance status, elevation of LDH, number
of involved sites, and liver involvement on survival.
DISCUSSION
Currently, a ‘gold standard’ of therapy in patients with adeno-
carcinoma or poorly differentiated CUP site (CUP syndrome) has
not been established. To date, only eight randomised trials have
been published in patients with CUP which have recruited 34–101
patients (Fizazi and Schmoll, 2006). Various chemotherapy
Recruited and 
randomly assigned (N=92) 
Carboplatin / paclitaxel (N=46)  Gemcitabine / vinorelbine (N=46) 
Not treated (N=1) Not treated (N=4)
- identification of primary (N=2)
inclusion criteria (N=1) - major violation of
inclusion criteria (N=2)
- severe liver failure (N=1)
- no histological proof
of disease (N=1)
Treated with Treated with
carboplatin / paclitaxel (N=42)  gemcitabine / vinorelbine (N=45) 
Primary analysis endpoint Primary analysis endpoint 
- practicability (N=42) - practicability (N=45)
Secondary analysis endpoints  Secondary analysis endpoints 
- overall survival (N=42)  - overall survival (N=45) 
- tumor response (N=38)
ineligible (N=4) ineligible (N=4)
- hypersensitivity reaction - withdrawal after identification  
during first/second cycle (N=3)
- treatment related death
after second cycle (N=1)
after first cycle (N=1)
after first cycle (N=1)
first cycle (N=1)
- acute pancreatitis after
- treatment related death
- tumor response (N=41) 
- acute coronary syndrome 
 cycle (N=1) 
  of primary tumor during first
randomisation (N=1) 
and > 2 months before  
- diagnostic tests incomplete 
- major violation of 
Figure 1 Trial profile, CONSORT diagram.
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sregimen have shown limited activity in numerous phase II trials,
resulting in response rates from 15 to 50% and a median survival
of 4–11 months. Selection bias is a major problem in phase II trials
in CUP because of the pronounced heterogeneity of the disease
and the tendency of physicians to include patients who seem to be
suited to the regimen under investigation. Thus, to obtain
clinically meaningful results, randomisation and multicentricity
are of major importance even in phase II trials.
On the basis of several phase II studies, platinum/taxane
combinations are widely used in patients with CUP, yielding
response rates of about 30% and a median survival of 7–11
months (Hainsworth et al, 1997; Briasoulis et al, 1998; Greco et al,
2002; Park et al, 2004; El-Rayes et al, 2005). Gemcitabine has also
gained considerable attraction recently. As first-line regimen,
gemcitabine combined with platinum or docetaxel achieved
response rates of 31–55% with a median survival of 8–10 months
(Culine et al, 2003; Pouessel et al, 2004; Pittman et al, 2006).
Our study was designed to investigate the widespread used
combination of carboplatin and paclitaxel and the non-platin/non-
taxane combination of gemcitabine and vinorelbine in patients
with CUP syndrome in a randomised multicenter study. Dosage
was chosen conservatively because of our concern of potentially
avoidable toxicity in other trials with larger doses in a cohort of
patients with palliative therapeutic intention. ‘Practicability’, a
Table 1 Patient characteristics
Arm A, n¼42
carboplatin/paclitaxel
Arm B, n¼45
gemcitabine/vinorelbine
Median age (range) 63 (31–77) 64 (46–75)
Male sex 23 (54.8%) 27 (60.0%)
ECOG performance score
0 14 (33.3%) 9 (20.0%)
1 20 (47.6%) 25 (55.6%)
2 5 (11.9%) 10 (22–2%)
No. of involved sites
1 6 (14.3%) 8 (17.8%)
2 10 (23.8%) 16 (35.6%)
3 18 (42.9%) 11 (24.4%)
43 8 (19%) 10 (22.2%)
Sites involved
Liver 23 (54.8%) 29 (64.4%)
Lung 14 (33.3%) 17 (37.8%)
Pleural effusion 3 (7.1%) 7 (15.6%)
Bones 8 (19.0%) 8 (17.8%)
Lymph nodes 27 (64.3%) 20 (44.4%)
Upper cervical 4 (9.5%) 2 (4.4%)
Supraclavicular 5 (11.9%) 4 (8.9%)
Axillary 4 (9.5%) 3 (6.7%)
Mediastinal 13 (31.0%) 10 (22.2%)
Abdominal 16 (38.1%) 11 (24.4%)
Peritoneum/ascites 5 (11.9%) 11 (24.4%)
Adrenal gland 4 (9.5%) 4 (8.9%)
Involvement above
diaphragm
4 (9.5%) 3 (6.7%)
Below diaphragm 15 (35.7%) 17 (37.8%)
Above and below 23 (54.8%) 25 (55.6%)
LDH4upper normal
limit
17 (40.5%) 18 (40.0%)
Table 2 Major toxicities
Arm A (% of patients) Arm B (% of patients)
Total Grade 3 Grade 4 Total Grade 3 Grade 4
Neutropenia 33.3 14.3 7.1 55.6 20.0 4.4
Thrombocytopenia 23.8 7.1 4.8 31.1 6.7 6.7
Fever/infection 26.2 2.4 2.4 46.7 8.9 2.2
Alopecia 73.8 16.7 2.4 22.2 2.2 0
Neurotoxicity 38.1 2.4 0 44.4 4.4 2.2
Nausea 52.4 0 0 62.2 11.1 0
Vomiting 23.8 0 0 31.1 0 2.2
Anorexia 23.8 9.5 0 37.8 15.6 0
Hypersensitivity 11.9 9.5 2.4 0 0 0
Table 3 Efficacy
Arm A Arm B
Practicable (95%-CI) as defined by 22 (52.4%; 36–68%) 19 (42.2%; 28–58%)
X2 cycles 39 (92.9%) 34 (75.6%)
Maximal delay 1 week 37 (88.1%) 34 (75.6%)
Survival X8 months 25 (59.5%) 20 (44.4%)
Response 10 (23.8%) 9 (20.0%)
Partial response (PR) 6 (14.3%) 4 (8.9%)
PR, unconfirmed 4 (9.5%) 5 (11.1%)
Stable disease 17 (40.5%) 15 (33.3%)
Progression 11 (26.2%) 17 (37.8%)
Not assessable 4 (9.5%) 4 (8.9%)
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Figure 3 Progression-free survival.
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srecently developed composite endpoint (Manegold et al, 2005)
combining overall survival of at least 8 months and the application
of at least 2 cycles of study treatment without significant delay was
chosen to avoid endpoints of limited clinical relevance like overall
response rate or progression-free survival in a palliative setting.
Although a formal comparison of both treatment arms was not
planned or performed, the study supports the importance of the
widely used platinum/taxane schedule as this arm fulfilled the
primary endpoint and reached a response rate of 23.8% and
additional 40.5% with stable disease, resulting in 64.3% of patients
with clinical benefit. The 1-year survival rate of 38%, the median
survival of 11 months, and the progression-free survival of 6.1
months are in the upper expected range in this high-risk
population of patients with CUP. Toxicity was tolerable and
manageable. The gemcitabine/vinorelbine regimen also showed
activity with a response rate of 20.0% and disease stabilisation in
additional 33.3% (clinical benefit in 53.3% of patients). The main
obstacle in this arm was the high early dropout rate with only
75.6% of patients receiving two or more cycles of therapy; partly
due to early progression of disease. The 1-year survival rate was
29%, the median and progression-free survival 7.0 and 3.2 months,
respectively. The rate of practicability was 42.2% with a 95% CI of
28–58%, including the 30% limit hypothesised; thus missing the
aim of the study.
In contrast to other studies no complete remissions were
observed in this study. This may be due to the inclusion of a high-
risk population with a median age of 63 years, more than one
involved site in 84%, liver involvement in 60%, and an ECOG
performance score worse than 0 in 74% of patients. Although we
applied a slightly lower dose of chemotherapy in the carboplatin/
paclitaxel arm than comparable studies, the median survival of 11
months argues against a deleterious effect of the dosage applied.
Moreover, these favourable results support the hypothesis that the
addition of a third chemotherapeutic substance may not be
beneficial in patients with CUP syndrome. In conclusion, the
results of our trial argue strongly against the omission of platinum
compounds and support the use of platinum/taxane combinations
for the first-line treatment of CUP syndrome.
However, the efficacy of chemotherapy was modest with the vast
majority of patients dying within 2 years which underlines the
urgent need for an optimisation of treatment, for example by
better characterisation of the tumour or validation of markers of
response prediction like ERCC1 for platinum, RRM1 for gemci-
tabine, and tubulin mutation for taxane. Specific tumour cell
profiles identified by gene expression microarrays may add to
establish a working diagnosis in CUP (Ismael et al, 2006; Huebner
et al, 2007; Bridgewater et al, 2008; Rosenfeld et al, 2008). The
future will show how these techniques can be used to optimise and
individualise patient care in CUP.
Another logical step is the addition of agents targeting the
vascular endothelial growth factor or the epithelial growth factor
receptor (EGFR) to an established chemotherapy regimen which
has increased the treatment efficacy, for example in colorectal,
breast, pancreatic, and NSCLC. Recent data have shown that for
EGFR inhibitors – at least in colorectal and lung cancer – the
mutational status of k-ras is a strong predictor of response efficacy
(Linardou et al, 2008) which may apply to CUP, too. A recent pilot
study combining bevacizumab and erlotinib in heterogeneous
patients has shown considerable efficacy in CUP with a median
overall survival of 7.4 months and 33% of patients alive at 1 year
(Hainsworth et al, 2007). A high level of EGFR expression of 66%
was observed in another study, with EGFR-expressing patients
responding considerably better to platinum-based therapy (Mas-
sard et al, 2007). The German CUP study group has recently
launched a randomised trial comparing the carboplatin/paclitaxel
regimen used in this study with and without cetuximab to test the
effectiveness of this EGFR inhibitor in patients with CUP.
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